| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Dietrich Büsselberg | Q42608731 |
| P2093 | author name string | Jennifer E McCallum | |
| Ana-Maria Florea | |||
| Elizabeth Varghese | |||
| Rama Rathore | |||
| P2860 | cites work | Structure-based design of potent, conformationally constrained Smac mimetics | Q95801450 |
| ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas | Q24290531 | ||
| Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain | Q24290943 | ||
| Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis | Q24294685 | ||
| IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis | Q24300707 | ||
| XIAP: cell death regulation meets copper homeostasis | Q24300814 | ||
| Final stages of cytokinesis and midbody ring formation are controlled by BRUCE | Q24308799 | ||
| cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms | Q24311676 | ||
| Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax | Q24323186 | ||
| cIAP1 Localizes to the nuclear compartment and modulates the cell cycle | Q24338725 | ||
| Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family | Q24550944 | ||
| Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis | Q24609324 | ||
| Survivin: a unique target for tumor therapy | Q26747332 | ||
| Cancer therapy in the necroptosis era | Q26766339 | ||
| Structural and biochemical basis of apoptotic activation by Smac/DIABLO | Q27626899 | ||
| Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152) | Q27678027 | ||
| Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP | Q27701663 | ||
| Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition | Q28115131 | ||
| Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1 | Q28144306 | ||
| Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis | Q28186614 | ||
| X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes | Q28189754 | ||
| Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond | Q28199137 | ||
| Die another way--non-apoptotic mechanisms of cell death | Q28240157 | ||
| Cell death: critical control points | Q28240722 | ||
| XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome | Q28271832 | ||
| Neuronal apoptosis-inhibitory protein does not interact with Smac and requires ATP to bind caspase-9 | Q28274451 | ||
| Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites | Q28275221 | ||
| Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function | Q28276098 | ||
| IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs | Q28291174 | ||
| Cell-cycle checkpoints and cancer | Q28293996 | ||
| Survivin splice variants regulate the balance between proliferation and cell death | Q28305497 | ||
| Apoptosis: a review of programmed cell death | Q28305845 | ||
| A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity | Q28483886 | ||
| An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI) | Q28485864 | ||
| A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors | Q28504926 | ||
| Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis | Q28511080 | ||
| Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA | Q28830560 | ||
| Structural Basis of Caspase Inhibition by XIAP | Q29011600 | ||
| Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma | Q29615607 | ||
| cIAP-2 block apoptotic events in bladder cancer cells | Q31154242 | ||
| Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma | Q33400365 | ||
| Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. | Q33435646 | ||
| Inhibiting the inhibitors: retro-inverso Smac peptides | Q33493623 | ||
| A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. | Q33515420 | ||
| Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. | Q33544118 | ||
| The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation | Q44932731 | ||
| PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q46202942 | ||
| A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells | Q46619108 | ||
| Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly | Q46890911 | ||
| Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy | Q47221521 | ||
| High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia | Q47406547 | ||
| Birc1e is the gene within the Lgn1 locus associated with resistance to Legionella pneumophila | Q48269403 | ||
| Whole-genome characterization of chemoresistant ovarian cancer. | Q50272478 | ||
| Expression of IAP family proteins and its clinical importance in breast cancer patients. | Q51022871 | ||
| Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. | Q52590107 | ||
| Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. | Q52621343 | ||
| Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. | Q53169400 | ||
| Expression of cIAP-1 correlates with nodal metastasis in squamous cell carcinoma of the tongue. | Q53466753 | ||
| Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. | Q53591297 | ||
| Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. | Q53609510 | ||
| The inhibitors of apoptosis (IAPs) as cancer targets | Q36851057 | ||
| DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer | Q36855596 | ||
| AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer | Q36919815 | ||
| Mechanisms of action of Bcl-2 family proteins | Q36932838 | ||
| Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs | Q36992161 | ||
| The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells | Q36992184 | ||
| Prognostic biomarkers of renal cell carcinoma: Recent advances | Q37197505 | ||
| IAP-targeted therapies for cancer | Q37302745 | ||
| Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma | Q37314736 | ||
| Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia | Q37355664 | ||
| Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma | Q37356468 | ||
| Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 | Q37412477 | ||
| SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. | Q37445045 | ||
| X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists | Q37454149 | ||
| Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic | Q37457562 | ||
| Following TRAIL's path in the immune system | Q37498946 | ||
| Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. | Q37574259 | ||
| Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale | Q37654710 | ||
| Molecular biology of Bax and Bak activation and action | Q37824965 | ||
| Targeting survivin in cancer: the cell-signalling perspective | Q37867746 | ||
| Death receptors as targets in cancer | Q38103591 | ||
| Cellular mechanisms controlling caspase activation and function | Q38111614 | ||
| Molecular pathways: targeting death receptors and smac mimetics | Q38211503 | ||
| X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. | Q38239689 | ||
| Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? | Q38242499 | ||
| The mitochondrial voltage-dependent anion channel 1 in tumor cells. | Q38275475 | ||
| Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. | Q38287054 | ||
| SADS: A new component of Fas-DISC is the accelerator for cell death signaling and is downregulated in patients with colon carcinoma | Q38305316 | ||
| Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines | Q38344110 | ||
| Mitochondrial apoptosis: killing cancer using the enemy within. | Q38367962 | ||
| Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. | Q38391583 | ||
| Small molecule inhibitor of apoptosis proteins antagonists: a patent review | Q38484840 | ||
| The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma. | Q38861440 | ||
| Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). | Q38928915 | ||
| Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process | Q36316624 | ||
| Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells | Q36431068 | ||
| A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment | Q36460712 | ||
| Hypoxia signalling in cancer and approaches to enforce tumour regression | Q36488739 | ||
| Survivin, a cancer target with an emerging role in normal adult tissues | Q36491426 | ||
| Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer | Q36547383 | ||
| Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy | Q36558024 | ||
| Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation | Q36604919 | ||
| The CASBAH: a searchable database of caspase substrates | Q36726238 | ||
| Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. | Q36746298 | ||
| Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. | Q36751715 | ||
| BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells | Q36824242 | ||
| The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock | Q36846723 | ||
| Detection of anti-livin antibody in gastrointestinal cancer patients. | Q54767281 | ||
| Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies | Q61776445 | ||
| Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways | Q73932730 | ||
| Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis | Q79857928 | ||
| Livin and Bcl-2 expression in high-grade osteosarcoma | Q80619467 | ||
| Expression and localization of inhibitor of apoptosis proteins in normal human tissues | Q81637512 | ||
| Detection of autoantibodies to livin and survivin in Sera from lung cancer patients | Q81648016 | ||
| Targeting apoptosis pathways in cancer therapy | Q81742188 | ||
| Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa | Q83988443 | ||
| Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors | Q84966132 | ||
| Bleomycin induced sensitivity to TRAIL/Apo-2L-mediated apoptosis in human seminomatous testicular cancer cells is correlated with upregulation of death receptors | Q38961445 | ||
| The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis | Q38970758 | ||
| Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells | Q38979846 | ||
| Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. | Q38982947 | ||
| Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models | Q39021475 | ||
| Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein | Q39068951 | ||
| Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis | Q39096643 | ||
| The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells | Q39195579 | ||
| Ardisianone, a natural benzoquinone, efficiently induces apoptosis in human hormone-refractory prostate cancers through mitochondrial damage stress and survivin downregulation. | Q39335751 | ||
| Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. | Q39370420 | ||
| Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer | Q39446582 | ||
| The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs | Q39511129 | ||
| Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-κB in colon cancer cells | Q39523519 | ||
| TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. | Q39737623 | ||
| XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma | Q39798856 | ||
| Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism | Q39985088 | ||
| Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome | Q40343583 | ||
| Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics | Q40513940 | ||
| Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis | Q40601815 | ||
| Increased survivin expression confers chemoresistance to tumor-associated endothelial cells | Q40645812 | ||
| Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells | Q40694264 | ||
| Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells | Q40877996 | ||
| The porin VDAC2 is the mitochondrial platform for Bax retrotranslocation. | Q41073152 | ||
| Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis | Q41536623 | ||
| Defining characteristics of Types I and II apoptotic cells in response to TRAIL. | Q41687820 | ||
| Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice | Q41752725 | ||
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Q42064781 | ||
| Phosphorylation of XIAP by CDK1-cyclin-B1 controls mitotic cell death | Q42113128 | ||
| The opposing roles of cellular inhibitor of apoptosis proteins in cancer | Q42288562 | ||
| CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. | Q42585598 | ||
| Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. | Q42713862 | ||
| Mitochondrial survivin - an Achilles' heel in cancer chemoresistance. | Q42730045 | ||
| Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. | Q42969753 | ||
| Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. | Q43903493 | ||
| Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ | Q44129457 | ||
| Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo | Q44590630 | ||
| IAP regulation of metastasis | Q33638504 | ||
| Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines | Q33861276 | ||
| Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. | Q33999606 | ||
| The rheostat in the membrane: BCL-2 family proteins and apoptosis | Q34038716 | ||
| Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide | Q34178083 | ||
| XIAP discriminates between type I and type II FAS-induced apoptosis | Q34205704 | ||
| Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription | Q34254214 | ||
| A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death | Q34346499 | ||
| Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. | Q34378269 | ||
| Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. | Q34488880 | ||
| Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis | Q34540067 | ||
| LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. | Q34542571 | ||
| Distribution of neuronal apoptosis inhibitory protein in human tissues. | Q34629464 | ||
| Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex | Q34646527 | ||
| Triggering caspase-independent cell death to combat cancer. | Q34688272 | ||
| Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode | Q34736820 | ||
| Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis | Q34802453 | ||
| X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton | Q34962925 | ||
| Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. | Q34982664 | ||
| Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response | Q34988055 | ||
| Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level | Q35051505 | ||
| The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury | Q35053511 | ||
| A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321 | Q35058595 | ||
| Overcoming resistance of cancer cells to apoptosis | Q35136082 | ||
| BRUCE regulates DNA double-strand break response by promoting USP8 deubiquitination of BRIT1. | Q35212757 | ||
| TRAIL and apoptosis induction by TNF-family death receptors. | Q35591708 | ||
| The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization | Q35632517 | ||
| Structural biology of the Bcl-2 family of proteins | Q35680498 | ||
| RETRACTED ARTICLE: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer | Q35941858 | ||
| Death receptor signaling | Q36011453 | ||
| Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer | Q36014277 | ||
| XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML | Q36034921 | ||
| IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis | Q36103378 | ||
| Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways | Q36184769 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P921 | main subject | inhibitor of apoptosis proteins | Q174299 |
| neoplasm | Q1216998 | ||
| antineoplastic resistance | Q13416904 | ||
| apoptotic process | Q14599311 | ||
| Smac/DIABLO protein | Q24741030 | ||
| mitochondrial protein | Q67455737 | ||
| intracellular signaling peptides and proteins | Q67575047 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 898-919 | |
| P577 | publication date | 2017-04-19 | |
| 2017-07-01 | |||
| P1433 | published in | Apoptosis | Q15749546 |
| P1476 | title | Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs) | |
| P478 | volume | 22 |
| Q92876679 | A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer |
| Q92941311 | Anti-Cancer Agents in Proliferation and Cell Death: The Calcium Connection |
| Q90241548 | Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy |
| Q92906084 | Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell |
| Q90576938 | CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation |
| Q91588484 | Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells |
| Q92819871 | Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer |
| Q92402767 | Cordycepin-induced unfolded protein response-dependent cell death, and AKT/MAPK-mediated drug resistance in mouse testicular tumor cells |
| Q64975715 | Countering TRAIL Resistance in Melanoma. |
| Q90235522 | CpG Oligodeoxynucleotide Promotes Apoptosis of Human Bladder Cancer T24 Cells Via Inhibition of the Antiapoptotic Factors |
| Q52608766 | Drug Repositioning in Glioblastoma: A Pathway Perspective. |
| Q61811849 | Flavonoids in Cancer and Apoptosis |
| Q64040347 | Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients |
| Q90749325 | Glucosamine Enhances TRAIL-Induced Apoptosis in the Prostate Cancer Cell Line DU145 |
| Q92757152 | Greensporone A, a Fungal Secondary Metabolite Suppressed Constitutively Activated AKT via ROS Generation and Induced Apoptosis in Leukemic Cell Lines |
| Q57268350 | Greensporone C, a Freshwater Fungal Secondary Metabolite Induces Mitochondrial-Mediated Apoptotic Cell Death in Leukemic Cell Lines |
| Q98623351 | In vitro analysis reveals necroptotic signaling does not provoke DNA damage or HPRT mutations |
| Q58700608 | MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2) |
| Q103804016 | Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant |
| Q58695632 | Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways |
| Q55302326 | Mutations in the P10 region of procaspase-8 lead to chemotherapy resistance in acute myeloid leukemia by impairing procaspase-8 dimerization. |
| Q91943280 | Overexpression of Smac by an Armed Vesicular Stomatitis Virus Overcomes Tumor Resistance |
| Q92885456 | PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1 |
| Q55340942 | Programmed cell death in yeast by thionin-like peptide from Capsicum annuum fruits involving activation of caspases and extracellular H+ flux. |
| Q58554204 | Promising Antineoplastic Actions of Melatonin |
| Q47654464 | Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression |
| Q90370565 | Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis |
| Q92914577 | Restoration of Mal overcomes the defects of apoptosis in lung cancer cells |
| Q91982383 | Sea Cucumber (Stichopus japonicas) F2 Enhanced TRAIL-Induced Apoptosis via XIAP Ubiquitination and ER Stress in Colorectal Cancer Cells |
| Q89554723 | Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance |
| Q59799448 | Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs |
| Q48203955 | Sex disparity in cancer: roles of microRNAs and related functional players. |
| Q94465297 | TWEAK Promotes the Proliferation of Squamous Cell Carcinoma Cells Through Activating cIAP1 Signals |
| Q61809001 | Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment |
| Q92702505 | The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy |
| Q48159758 | The STAT3/NFIL3 signaling axis-mediated chemotherapy resistance is reversed by Raddeanin A via inducing apoptosis in choriocarcinoma cells. |
| Q42658239 | Two Active Compounds from Caesalpinia sappan L. in Combination with Cisplatin Synergistically Induce Apoptosis and Cell Cycle Arrest on WiDr Cells |
| Q90041185 | XIAP as a Target of New Small Organic Natural Molecules Inducing Human Cancer Cell Death |
| Q60215147 | p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors |
Search more.